Somatropin - Novo Nordisk
Alternative Names: NN-1610; NN-220; Norditropin; Norditropin cartridge; Norditropin FlexPro; Norditropin NordiFlex; Norditropin NordiLet; Norditropin NordiPen; Norditropin S; Norditropin SimpleXxLatest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Novo Nordisk
- Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
- Mechanism of Action Human growth hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Dwarfism; Growth disorders; Short stature; Somatotropin deficiency
- Discontinued Female infertility; Fracture; Nutrition disorders
Most Recent Events
- 01 Mar 2022 Launched for Short stature (In children) in France (SC) before March 2022 (NCT05308927)
- 09 Jul 2019 Discontinued - Phase-III for Short stature (In children) in South Korea (SC) as no development reported after, December 2014 (NCT01778023)
- 12 Jul 2018 Novo Nordisk completes a phase III trial in Short Stature (In children with Noonan Syndrome) in Japan (NCT01927861)